{
    "nctId": "NCT03425773",
    "briefTitle": "Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care",
    "officialTitle": "Single Center, Open-label, Accelerated Titration, Multiple Dosing Study to Evaluate the Safety, Tolerability, Immune Response and Pre-efficacy of BVAC-B in Patients With Progressive or Recurrent HER2/Neu Positive Gastric Cancer After Failure to Standard Care",
    "overallStatus": "COMPLETED",
    "conditions": "Stomach Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 8,
    "primaryOutcomeMeasure": "Evaluate Maximum tolerated dose(MTD) for phase 2 trial",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Progressive or recurrent HER2/neu positive(IHC 1+\u2265) gastric cancer\n* Received 1 or more chemotherapy or radiotherapy as prior therapy for progressive or recurrent tumor lesion\n* At least 1 measurable lesion according to RECIST(ver 1.1)\n* Ages above 19\n* ECOG performance status between 0 to 2\n* Patients meets the blood test standards in the screening test\n* Patients meets the blood chemistry test standards in the screening test\n* Patients who has agreed to a medically accepted contraceptive in this clinical trial\n* Patients at least six months or more of survival can be expected\n* Patients decided to participate in this clinical trial and signed written informed consent\n\nExclusion Criteria:\n\n* Histopathology is a neuroendocrine or small cell carcinoma\n* History of brain metastasis or signs of brain metastasis\n* Clinical diagnosis of hepatitis C or hepatitis B\n* Clinical diagnosis of human immunodeficiency virus (HIV)\n* History of HIV infection\n* Patients with heart failure, coronary artery disease(CAD) or Myocardial infarction in 6 month prior to screening. (LVEF is lower than 50% in screening visit)\n* Administered the drug for other clinical trials within 4weeks before participate in this trial\n* Administered any vaccines within 4weeks before participate in this trial (4 weeks for live vaccine, 2 weeks for other inactivated vaccine)\n* Administered the granulocytes concentrates within 3 months before the screening visit\n* Received chemotherapy or radiation therapy within 2 weeks before the 1st administration of investigational drug(BVAC-B)\n* Received following formulation within 1 months before the screening visit : Chronic steroids(more than 5 days), immunosuppressant or immunomodulatory agents. G-CSF\n* Patients who have participated in the clinical trial of a immunotherapeutic vaccine within 1 year or immunotherapy within 3 months before the screening visit\n* Patients who is pregnant or breast-feeding\n* Patients who researchers has determined that participation in the clinical trial is inappropriate\n* Suspected to have other progressive cancer or malignant tumor needs treatment in 3 years. Completely treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, thyroid carcinoma, cervical intraepithelial neoplasia are not included",
    "sex": "ALL",
    "minimumAge": "19 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}